S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
OTCMKTS:BIOAF

Bioasis Technologies Stock Forecast, Price & News

$0.21
+0.01 (+5.04%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.19
$0.21
50-Day Range
$0.19
$0.25
52-Week Range
$0.18
$0.45
Volume
1,500 shs
Average Volume
25,727 shs
Market Capitalization
$15.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.05
30 days | 90 days | 365 days | Advanced Chart
Receive BIOAF News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioasis Technologies and its competitors with MarketBeat's FREE daily newsletter.


Bioasis Technologies logo

About Bioasis Technologies

biOasis Technologies, Inc. operates as a biopharmaceutical company. It focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in Guilford, CT.

Headlines

Bioasis Technologies Inc (BIOAF)
January 16, 2022 |  nasdaq.com
BIOAF: Second Quarter Update
November 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Drugs, proprietaries, & sundries
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BIOAF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.06 million
Cash Flow
$0.01 per share

Profitability

Net Income
$520 thousand
Pretax Margin
27.80%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$15.03 million
Optionable
Not Optionable

Company Calendar

Last Earnings
1/19/2022
Today
1/25/2022
Fiscal Year End
2/28/2022

MarketRank

Overall MarketRank

0.95 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Bioasis Technologies (OTCMKTS:BIOAF) Frequently Asked Questions

How has Bioasis Technologies' stock been impacted by COVID-19 (Coronavirus)?

Bioasis Technologies' stock was trading at $0.1545 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIOAF shares have increased by 34.9% and is now trading at $0.2084.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Bioasis Technologies?

Bioasis Technologies saw a decrease in short interest in December. As of December 31st, there was short interest totaling 1,500 shares, a decrease of 95.4% from the December 15th total of 32,500 shares. Based on an average trading volume of 28,900 shares, the days-to-cover ratio is currently 0.1 days.
View Bioasis Technologies' Short Interest
.

How were Bioasis Technologies' earnings last quarter?

Bioasis Technologies Inc. (OTCMKTS:BIOAF) posted its quarterly earnings results on Wednesday, January, 19th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02).
View Bioasis Technologies' earnings history
.

Who are Bioasis Technologies' key executives?

Bioasis Technologies' management team includes the following people:
  • Deborah A. Rathjen, Executive Chairman, President & CEO
  • Caroline Dircks, Chief Operating Officer
  • Dave Jenkins, Chief Financial Officer
  • Mei Mei Tian, Vice President & Head-External Research
  • Graeme Dick, Director-Investor Relations

Who are some of Bioasis Technologies' key competitors?

What is Bioasis Technologies' stock symbol?

Bioasis Technologies trades on the OTCMKTS under the ticker symbol "BIOAF."

How do I buy shares of Bioasis Technologies?

Shares of BIOAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioasis Technologies' stock price today?

One share of BIOAF stock can currently be purchased for approximately $0.21.

How much money does Bioasis Technologies make?

Bioasis Technologies has a market capitalization of $15.03 million and generates $3.06 million in revenue each year. The company earns $520 thousand in net income (profit) each year or ($0.02) on an earnings per share basis.

What is Bioasis Technologies' official website?

The official website for Bioasis Technologies is www.bioasis.us.

Where are Bioasis Technologies' headquarters?

Bioasis Technologies is headquartered at 14 Water Street, Guilford CT, 06437.

How can I contact Bioasis Technologies?

Bioasis Technologies' mailing address is 14 Water Street, Guilford CT, 06437. The company can be reached via phone at (203) 533-7082 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.